Secures New Debt Financing of up to $125M Maturing in 2030 with Plans to Retire $200M in Prior Debt Reports Unaudited Fourth-Quarter Revenue of $29 million and 2024 Revenue of $113 million SAN JOSE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it has entered into a definitive securities purchase agreement for a private placement ...

Management Changes - Osisko Metals has made significant changes to its leadership team, appointing John F. Burzynski as Director and Executive Chairman, Don Njegovan as President, Blair Zaritsky as Chief Financial Officer, Amanda Johnston as Vice President of Finance, Alexandria Marcotte as Vice President of Exploration, and promoting Lili Mance to Vice President, Corporate Secretary [2] - Patrick Anderson and Tara Christie have been appointed to the Board of Directors, bringing extensive experience in the resource sector [2][3][4] - Luc Lessard has resigned as a director but will continue as a strategic advisor, while Anthony Glavac has stepped down as Chief Financial Officer [5][6] Stock Option Grants - The company has granted a total of 15,100,000 stock options to certain directors, officers, employees, and consultants, with an exercise price of $0.26 per share and a five-year term [6][7] Company Overview - Osisko Metals is focused on exploration and development in the critical metals sector, particularly copper and zinc, having acquired a 100% interest in the Gaspé Copper mine in July 2023, which has Indicated Mineral Resources of 824 million tonnes grading 0.34% CuEq and Inferred Mineral Resources of 670 million tonnes grading 0.38% CuEq [8] - The company is also advancing the Pine Point project, which has Indicated Mineral Resources of 49.5 million tonnes at 5.52% ZnEq and Inferred Mineral Resources of 8.3 million tonnes at 5.64% ZnEq [9]

NEW YORK, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Outset Medical, Inc. (NASDAQ: OM) on behalf of long-term stockholders following a class action complaint that was filed against Outset Medical on August 29, 2024 with a Class Period from August 1, 2022 to August 7, 2024. Our investigation concerns whether the board of directors of Outset Medical have breached their fiduciary duties to the com ...

SAN JOSE, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will present at the 2024 Stifel Healthcare conference on Tuesday, November 19, 2024, at 10:20 a.m. Eastern time. A live and archived webcast of the presentation will be available on the “Investors” section of the Outset website at https://investors.outs ...

Outset Medical, Inc. (OM) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.71 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 7.14%. A quarter ago, it was expected that this company would post a loss of $0.43 per share when it actually produced a loss of $0.47, delivering a surprise of -9.30%.Over the last four quarters, the company has surpas ...

SAN JOSE, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the third quarter ended September 30, 2024. “During the quarter, we made significant progress, achieving sequential revenue growth, expanding the Tablo footprint in both the acute and home care settings, boosting gross margin compared to last year an ...

NEW YORK, Oct. 28, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Outset Medical, Inc. (NASDAQ: OM).Shareholders who purchased shares of OM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/outset-medical-loss-submission-form/?id=109396&from=4CLASS PERIOD: September 15, 2020 to ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Outset Medical, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the lawsuit is from September 15, 2020, to August 7, 2024 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by October 28, 2024, to serve as lead plaintiff [1] Group 2: Allegations Against Outset Medical - The lawsuit alleges that Outset Medical made false and misleading statements regarding the FDA clearance for the TabloCart, which was not obtained [3] - It is claimed that Outset promoted continuous renal replacement therapy (CRRT) as FDA-approved for the Tablo, which was inaccurate [3] - The company reportedly lacked the necessary sales team and processes to effectively ramp up Tablo sales [3] - Allegations include inadequate internal controls leading to improper marketing and misleading financial statements [3] - The lawsuit asserts that the positive statements made by the defendants about the company's business were materially misleading [3]

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Oct. 23, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Outset Medical, Inc. ("Outset" or the "Company") (NASDAQ:OM) investors of a class action representing investors that bought securities between Aug. 1, 2022 and Aug. 7, 2024, inclusive (the "Class Period"). Outset investors have until Oct. 28, 2024 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, b ...

Outset Medical features patient experience posterpresentations at Kidney Week 2024 Consensus recommendations for use of catheters in home hemodialysis patients published in Kidney Medicine SAN JOSE, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset″), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced two new research posters that demonstrate significant quality of life and mental health ben ...